Navigation Links
Damon Runyon Cancer Research Foundation awards $2.25M to 5 top young clinical investigators
Date:6/20/2008

New York, NY -- The Damon Runyon Cancer Research Foundation named 5 new Damon Runyon Clinical Investigators at its May 2008 Clinical Investigator Award Committee review. The recipients of this prestigious, three-year award are outstanding early career physician-scientists conducting patient-oriented cancer research at major research centers under the mentorship of the nation's leading scientists and clinicians. Each will receive $450,000 to support the development of his or her cancer research program. The Clinical Investigator Award program is specifically intended to help address the worrisome shortage of physicians capable of translating scientific discovery into new breakthroughs for cancer patients. In partnerships with founding sponsor Eli Lilly and Company, and with Siemens Medical Solutions, Novartis and Genentech, the Damon Runyon Cancer Research Foundation has committed more than $30 million to support the careers of 44 physician-scientists across the United States since 2000.

2008 Clinical Investigator Awardees

  • Ronald J. Buckanovich, MD, PhD

    By combining tumor cells and embryonic stem cells, Dr. Buckanovich has developed a new animal model of ovarian cancer that develops abundant tumor blood vessels, or vasculature. He is using this model to first characterize molecular markers of tumor vasculature, and then therapeutically target them with antibodies coupled to toxic nanoparticles. He also seeks to identify and characterize a population of cells, cancer stem cells, which play a critical role in tumor establishment and growth. These discoveries could lead to highly effective targeted therapies. Dr. Buckanovich works under the mentorship of Daniel F. Hayes, MD, and Max S. Wicha, MD, at the University of Michigan, Ann Arbor, Michigan.

  • Andrew T. Chan, MD, MPH

    Dr. Chan is developing molecular "smart" probes and novel imaging techniques for earlier and improved detection of colorectal cancer. He will soon be testing this promising technology in clinical trials. In addition, this work has the potential to accelerate the discovery and development process for therapeutic and chemopreventative agents in colorectal cancer. Dr. Chan works under the mentorship of Charles S. Fuchs, MD, MPH, and Ralph Weissleder, MD, PhD, at the Massachusetts General Hospital, Boston, Massachusetts.

  • Rachael A. Clark, MD, PhD

    Dr. Clark is investigating the role of the immune system in controlling squamous cell carcinomas of the skin. She has identified new mechanisms by which these skin tumors evade the immune system: disruption of T cell homing and recruitment of regulatory T cells. Her studies focus on developing new therapies for effective treatment of these cancers. Dr. Clark works under the mentorship of Thomas S. Kupper, MD, at Brigham and Women's Hospital, Boston, Massachusetts.

  • Vassiliki Karantza-Wadsworth, MD, PhD

    Autophagy is a process of "cellular self-digestion" that is used by both normal cells and tumor cells as a survival mechanism in times of metabolic stress, such as nutrient and oxygen deprivation. Dr. Karantza-Wadsworth is examining the role of autophagy in tumor cell survival and responsiveness to chemotherapy. She is performing preclinical and clinical studies modulating autophagy in breast cancer, which could lead to improved patient response to treatment. Dr. Karantza-Wadsworth works under the mentorship of Eric H. Rubin, MD, at UMDNJ/Robert Wood Johnson Medical School, New Brunswick, New Jersey.

  • Elahe A. Mostaghel, MD, PhD

    Suppression of the hormone testosterone is currently the most effective treatment for advanced prostate cancer; however, tumors frequently develop resistance to this therapy. Dr. Mostaghel is defining key mechanisms underlying this resistance to hormone treatment. Her goal is to develop novel treatments for prostate cancer that can be rapidly moved into the clinic. Dr. Karantza-Wadsworth works under the mentorship of Peter S. Nelson, MD, at the Fred Hutchinson Cancer Research Center, Seattle, Washington.


'/>"/>

Contact: Yung S. Lie, PhD
yung.lie@damonrunyon.org
212-455-0520
Damon Runyon Cancer Research Foundation
Source:Eurekalert

Related medicine news :

1. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 14 top young investigators
2. Damons Grill Completes Move to Trans Fat-Free Menu
3. CT Screens for Lung Cancer Not a Cure-All
4. Pro Baseball Helps Keep Skin Cancer From Scoring
5. Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland through Irelands First Nationwide Cervical-Cancer Screening Program
6. American Academy of Dermatology, Major League Baseball and Major League Baseball Players Association Play Sun Smart(TM) to Strike Out Skin Cancer
7. Lack of CHFR gene expression sets stage for breast cancer
8. 10th World Congress on Gastrointestinal Cancer -- Barcelona, Spain
9. Vitamin D May Promote Colon Cancer Survival
10. Study links vitamin D to colon cancer survival
11. Cancer Drug Gleevec Linked to Muscle Damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... New York, New York (PRWEB) , ... May 24, 2017 , ... ... and general vascular surgery in New York City. He is known for ... his broad specialization in vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular ...
(Date:5/24/2017)... ... 2017 , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now ... a referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take ... Patients no longer need to feel the esthetic effects of wires and brackets when ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As a ... advancements in his field by attending numerous CE courses each year. His recent ...
(Date:5/24/2017)... ... 24, 2017 , ... If you are thinking of a visit to San Francisco , ... is the perfect time to visit. , Business Architecture Associates is pleased to offer 5 ... individuals, as a 4-½ day package for individuals, and as 4-½ day corporate package for ...
(Date:5/24/2017)... Falls, Wisconsin (PRWEB) , ... May 24, 2017 ... ... leader in clean label food ingredient solutions for the food and beverage industry ... factor in food ingredient statements during the purchasing decision process. As a result, ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... JERUSALEM , May 9, 2017  Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... today that the Canadian Intellectual Property Office has ... for Oral Administration of Exenatide". The patent covers ... analog. GLP-1 is an incretin hormone ...
(Date:5/6/2017)... 5, 2017   Provista , a proven leader in ... customers, today announced Jim Cunniff as the company,s ... and business experience to Provista, including most recently serving as ... California . He assumed his new role with ... great fit for Provista," says Jody Hatcher , president, ...
(Date:5/4/2017)... 2017  A recent study published in the ... light as a means of disinfection anesthesia workstations ... bioburden on anesthesia workstations. In the study, UVC ... medical equipment surfaces contaminated with three (3) organisms ... study further validates the body of literature supporting ...
Breaking Medicine Technology: